On the other hand, naringenin has beneficial effects on osteosarcoma patients as follows: it can improve antioxidant capacities of osteosarcoma patients by increasing the serum levels of SOD and GSH and reducing the serum levels of AST and ALT; it can improve lipid profile of osteosarcoma patients by improving the serum levels of HDL-C and reducing the serum levels of TG, TC, LDL-C, and MDA; and it can improve the anti-inflammatory capacities of osteosarcoma patients by reducing the serum levels of IL-1 beta and IL-6. This evidence concerns the gene IL1B and osteosarcoma.